A groundbreaking blood test may soon predict Alzheimer’s disease in healthy older adults years before symptoms like memory loss appear, according to new research. The test measures levels of a protein called p-tau217, which correlates with brain plaque buildup—a hallmark of Alzheimer’s.
Key Findings
Researchers reported that individuals with the highest p-tau217 levels had a 38% risk of developing cognitive impairment within five years and a 78% risk within a decade. The study, published in JAMA and presented at the Alzheimer’s Association International Conference, analyzed data from 2,684 healthy older adults.
Current Limitations
While the test shows promise, experts caution against widespread use for now. Dr. Reisa Sperling of Mass General Brigham Neuroscience Institute emphasized that the test is not yet ready for clinical use in healthy individuals. Instead, it could help identify high-risk volunteers for clinical trials testing potential Alzheimer’s treatments.
Broader Implications
The test could accelerate drug development by enabling researchers to enroll high-risk participants in prevention trials. Dr. Manisha Parulekar of Hackensack University Medical Center noted that early detection could also allow for personalized interventions, such as lifestyle changes to reduce risk. However, she warned of potential psychological distress and ethical concerns, such as insurance discrimination, if the test becomes widely available.
Next Steps
Researchers stress the need for further validation before the test is used in clinical settings. For now, they recommend focusing on general health practices—such as exercise, a balanced diet, and mental engagement—to lower Alzheimer’s risk.